RP1 + nivolumab
Non-Melanoma Skin Cancers (Merkel cell carcinoma, Basal cell carcinoma, Angiosarcoma)
Key Facts
Indication
Non-Melanoma Skin Cancers (Merkel cell carcinoma, Basal cell carcinoma, Angiosarcoma)
Phase
Phase 2
Status
Active, in IGNYTE trial
Company
About Replimune
Founded in 2015, Replimune is at the forefront of developing next-generation oncolytic immunotherapies with the mission to revolutionize cancer treatment. Its lead candidate, RP1 (vusolimogene odeparepvec), has a PDUFA date of July 22, 2025, for advanced melanoma and is being studied across multiple skin cancers. The company's wholly-owned RPx platform and in-house manufacturing capability position it to develop a broad portfolio of treatments aimed at overcoming resistance to current immunotherapies.
View full company profile